Description
Nobivac Canine 3-DAPv recommended for the vaccination of healthy dogs for prevention of disease caused by canine distemper virus and canine parvovirus and as an aid in the prevention of disease caused by canine adenovirus (both infectious canine hepatitis and infectious tracheobronchitis) for up to three years following initial and booster vaccinations.
Canine Distemper, Adenovirus Type 2, Parvovirus, MODIFIED LIVE VIRUS
Proven 3-year vaccine that offers comprehensive protection against 3 highly contagious canine viruses.
Provides broad coverage against canine distemper virys, canine adenovirus type 2 (CAV-2), and canine parvovirus (CPV) Challenve studies in dogs showed 100% protection over 3 years against distemper, adenovirys type 1, and parvovirus1 Used formulation containing CPV STRAIN 154®, able to override maternal antibodies at an early age1-2 Serologic tests demonstrated high antibody titers throughout the 3-year post-vaccination isolation period1 Manhattan strain of CAV-2 was used to confer protection against canine infetious hepatitis caused by canine adenovirus type 1 (CAV-1) without eliciting the adverse reactions associated with CAV-1 vacciens1 Protects against the commonly spread canine distemper virus Protects against all field strains of CPV currently seen Prevents both infectious canine hepatitis caused by CAV-1 and infectious tracheobronchitis associated with CAV-2
Indications Approved for the vaccination of healthy dogs for the prevention of disease caused by canine distemper virus and as an aid in the prevention of disease caused by canine adenovirus (both infectious canine hepatitis and infectious tracheobronchitis) for up to 3 years following initial and booster vaccinations Recommended for use in health dogs 7 weeks of age or older
Nobivac is a registered trademark of Intervet Inc., d/b/a Merck Animal Health, a subsidiary of Merck & Co. Inc.
Directions
Initial 1ml dose given by substaneous route to health dogs as early as 7 weeks of age
1ml booster doses given every 3 to 4 weeks untul 12 weeks of age
Dogs over 12 weeks of age should initially receive 2 doses 3-4 weeks apart
Revaccination every 3 years with a single dose thereafter
Safety Information:
Can be safely administered to dogs as young as 7 weeks of age
High-titer CPV and canine distemper virus strains proven safe for dogs as young as 4 weeks of age. 2
No injection site or vaccine-related reactions reported during challenge studies
PRECAUTIONS:
Store at 2°-7°
Do not freeze.
Do not mix with other vaccines.
Use new, non-chemically sterilized needles and syringes.
Burn vaccine container and all unused contents.
WARNINGS:
Contains gentamicin as a preservative.
Vaccinate only health, non-parasitized dogs.
Do not vaccinate pregnant bitches.
The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions. Antidote: Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction.
The age at which maternal antibody for canine parvovirus no longer interferes with the development of active immunity varies according to the bitch's titer and quantity of colostral antibodies absorbed by the puppy.